ERBB2 and breast carcinoma: This type of breast cancer has poor prognosis, strong invasiveness, and a high recurrence rate (Slamon et al., 1987), so drugs for targeted therapy of HER2 positive breast cancer are good for HER2 positive patients mostly in the early stages of their disease.